Study Summary
This trial is testing whether CO2 can help people with POTS by lowering heart rate and reducing symptoms when upright/standing.
Eligible Conditions
- Postural Orthostatic Tachycardia Syndrome
- Orthostatic Intolerance
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: difference between HR from supine to peak HR during tilt test for each intervention (mean value HR between the 8th and 9th minute of supine; peak parameters, during HUTT, mean value during the first min and between the 3rd and 8th min)
VOSS will be accessed at the 8th minute of each HUTT, comparing the intensity of symptoms in each intervention
VOSS symptom score
difference between CBFv from supine to peak during tilt test for each intervention (mean value CBFv between the 8th and 9th min of supine; peak parameters, during HUTT, mean value CBFv during the first min and between the 3rd and 8th min)
Cerebral blood flow velocity (CBFv) variation
difference between HR from supine to peak HR during tilt test for each intervention (mean value HR between the 8th and 9th minute of supine; peak parameters, during HUTT, mean value during the first min and between the 3rd and 8th min)
Heart Rate (HR) variation
Trial Safety
Safety Progress
Trial Design
0 Treatment Group
26 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: difference between hr from supine to peak hr during tilt test for each intervention (mean value hr between the 8th and 9th minute of supine; peak parameters, during hutt, mean value during the first min and between the 3rd and 8th min)
Who is running the clinical trial?
University of CalgaryLead Sponsor
706 Previous Clinical Trials
493,675 Total Patients Enrolled
6 Trials studying Postural Orthostatic Tachycardia Syndrome
487 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Satish R Raj, MD, MSCIPrincipal InvestigatorUniversity of Calgary, Cardiac Science
4 Previous Clinical Trials
261 Total Patients Enrolled
2 Trials studying Postural Orthostatic Tachycardia Syndrome
157 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Eligibility Criteria
Age 18 - 60 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are able to travel to the University of Calgary.
You are not a smoker.
References
- Ocon, Anthony J., Marvin S. Medow, Indu Taneja, Debbie Clarke, and Julian M. Stewart. 2009. “Decreased Upright Cerebral Blood Flow and Cerebral Autoregulation in Normocapnic Postural Tachycardia Syndrome”. American Journal of Physiology-heart and Circulatory Physiology. American Physiological Society. doi:10.1152/ajpheart.00138.2009.
- Novak, Peter. 2018. “Hypocapnic Cerebral Hypoperfusion: A Biomarker of Orthostatic Intolerance”. Edited by Ferenc Gallyas. Plos One. Public Library of Science (PLoS). doi:10.1371/journal.pone.0204419.
- Taneja, Indu, Marvin S. Medow, Debbie A. Clarke, Anthony J. Ocon, and Julian M. Stewart. 2011. “Baroreceptor Unloading in Postural Tachycardia Syndrome Augments Peripheral Chemoreceptor Sensitivity and Decreases Central Chemoreceptor Sensitivity”. American Journal of Physiology-heart and Circulatory Physiology. American Physiological Society. doi:10.1152/ajpheart.01211.2010.
- Stewart, Julian M., Paul Pianosi, Mohamed A. Shaban, Courtney Terilli, Maria Svistunova, Paul Visintainer, and Marvin S. Medow. 2018. “Postural Hyperventilation as a Cause of Postural Tachycardia Syndrome: Increased Systemic Vascular Resistance and Decreased Cardiac Output When Upright in All Postural Tachycardia Syndrome Variants”. Journal of the American Heart Association. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/jaha.118.008854.
- Del Pozzi, Andrew T., Christopher E. Schwartz, Deepali Tewari, Marvin S. Medow, and Julian M. Stewart. 2014. “Reduced Cerebral Blood Flow with Orthostasis Precedes Hypocapnic Hyperpnea, Sympathetic Activation, and Postural Tachycardia Syndrome”. Hypertension. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/hypertensionaha.113.02824.
- Stewart JM, Pianosi P, Shaban MA, Terilli C, Svistunova M, Visintainer P, Medow MS. Postural Hyperventilation as a Cause of Postural Tachycardia Syndrome: Increased Systemic Vascular Resistance and Decreased Cardiac Output When Upright in All Postural Tachycardia Syndrome Variants. J Am Heart Assoc. 2018 Jun 30;7(13):e008854. doi: 10.1161/JAHA.118.008854.
- 2022. "Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04271878.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments